314
Views
2
CrossRef citations to date
0
Altmetric
Review

Biologics and immunomodulators for treating Crohn’s disease developing after surgery for an initial diagnosis of ulcerative colitis: a review of current literature

, , &
Pages 813-817 | Received 31 Jan 2018, Accepted 15 Apr 2018, Published online: 02 May 2018

References

  • Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89:1553–1563.
  • Braveman JM, Schoetz DJ, Marcello PW, et al. The fate of the ileal pouch in patients developing Crohn’s disease. Dis Colon Rectum. 2004;47:1613–1619.
  • de Oca J, Sánchez-Santos R, Ragué JM, et al. Long-term results of ileal pouch–anal anastomosis in Crohn’s disease. Inflamm Bowel Dis. 2003;9:171–175.
  • Feuerstein JD, Cheifetz AS. Crohn disease: epidemiology, diagnosis, and management. Mayo Clin Proc. 2017;92:1088–1103.
  • Melton GB, Fazio VW, Kiran RP, et al. Long-term outcomes with ileal pouch-anal anastomosis and Crohn's disease: pouch retention and implications of delayed diagnosis. Ann Surg. 2008;248:608–616.
  • Shen B. Crohn's disease of the ileal pouch: reality, diagnosis, and management. Inflamm Bowel Dis. 2008;15:284–294.
  • Shen B, Fazio VW, Remzi FH, et al. Clinical features and quality of life in patients with different phenotypes of Crohn’s disease of the ileal pouch. Dis Colon Rectum. 2007;50:1450–1459.
  • Wolf JM, Achkar J-P, Lashner BA, et al. Afferent limb ulcers predict Crohn’s disease in patients with ileal pouch-anal anastomosis. Gastroenterology. 2004;126:1686–1691.
  • Kariv R, Plesec T, Lopez R, et al. P-0056: pyloric gland metaplasia-a novel histological marker for Crohn's disease of the pouch and refractory pouchitis. Inflamm Bowel Dis. 2007;13:665.
  • Austin GL, Herfarth HH, Sandler RS. A critical evaluation of serologic markers for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:545–547.
  • Benor S, Russell GH, Silver M, et al. Shortcomings of the inflammatory bowel disease Serology 7 panel. Pediatrics. 2010;125:1230–1236.
  • Colombel J-F, Ricart E, Loftus Jr EV, et al. Management of Crohn’s disease of the ileoanal pouch with infliximab. Am J Gastroenterol. 2003;98:2239–2244.
  • Hahnloser D, Pemberton J, Wolff B, et al. Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Br J Surg. 2007;94:333–340.
  • Fazio VW, Kiran RP, Remzi FH, et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg. 2013;257:679–685.
  • Ricart E, Panaccione R, Loftus EV, et al. Successful management of Crohn’s disease of the ileoanal pouch with infliximab. Gastroenterology. 1999;117:429–432.
  • Haveran LA, Sehgal R, Poritz LS, et al. Infliximab and/or azathioprine in the treatment of Crohn’s disease-like complications after IPAA. Dis Colon Rectum. 2011;54:15–20.
  • Kelly OB, Rosenberg M, Tyler AD, et al. Infliximab to treat refractory inflammation after pelvic pouch surgery for ulcerative colitis. J Crohns Colitis. 2015;10:410–417.
  • Ferrante M, D'haens G, Dewit O, et al. Efficacy of infliximab in refractory pouchitis and Crohn’s disease-related complications of the pouch: a Belgian case series. Inflamm Bowel Dis. 2009;16:243–249.
  • Kooros K, Katz AJ. Infliximab therapy in pediatric Crohn’s pouchitis. Inflamm Bowel Dis. 2004;10:417–420.
  • Shen B, Remzi F, Lavery I, et al. Administration of adalimumab in the treatment of Crohn’s disease of the ileal pouch. Aliment Pharmacol Ther. 2009;29:519–526.
  • Li Y, Lopez R, Queener E, et al. Adalimumab therapy in Crohn’s disease of the ileal pouch. Inflamm Bowel Dis. 2012;18:2232–2239.
  • Robbins L, Zaghiyan K, Melmed G, et al. Outcomes with anti-tumour necrosis factor-alpha therapy and serology in patients with Denovo Crohn’s disease after ileal pouch anal anastomosis. J Crohns Colitis. 2016;11:77–83.
  • Feuerstein JD, Cullen G, Cheifetz AS. Immune-mediated reactions to anti-tumor necrosis factors in inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:1176–1186.
  • Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013;369:754–762.
  • Targownik LE, Bernstein CN. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol. 2013;108:1835.
  • Dulai PS, Siegel CA, Colombel J-F, et al. Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD. Gut. 2014;63:1843–1853.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.